Overview

MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma

Status:
Active, not recruiting

Trial end date:
2022-06-01

Target enrollment:

Participant gender:

Summary

This research study tests a new medicine for mobilizing stem cells so they can be collected and used for autologous stem cell transplant for treatment of multiple myeloma. MGTA-145, the new medicine, will be given with plerixafor.

Phase:

Phase 2

Details

Lead Sponsor:

Stanford University

Collaborator:

National Institutes of Health (NIH)

Treatments:

Plerixafor
Plerixafor octahydrochloride